New Delhi: Drug firm Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir used for treatment and prevention of influenza.
“Zydus’ Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6 mg/ml”, Zydus Cadila said in a statement.
The product is used in the treatment and prevention of influenza, it added.
The drug will be produced at Nesher Pharmaceuticals’ manufacturing facility located at St Louis, US, Zydus Cadila said.
The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company’s filing process.
Latest posts by supriya kashyap (see all)
- Natco’s partner Alvogen gets nod for influenza drug in US - November 6, 2017
- USFDA moves to more efficient global pharmaceutical manufacturing inspections - November 6, 2017
- Sanofi refines expectations on drop in sales at diabetes arm - November 6, 2017